Halozyme Therapeutics Inc (HALO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Halozyme Therapeutics Inc (HALO) has a cash flow conversion efficiency ratio of 0.354x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($178.60 Million) by net assets ($503.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Halozyme Therapeutics Inc (HALO) balance sheet quality index to measure how much of total assets are equity-financed.
Halozyme Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Halozyme Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HALO cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Halozyme Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Halozyme Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Viper Energy Ut
NASDAQ:VNOM
|
0.032x |
|
Companhia Paranaense de Energia - COPEL
NYSE:ELPC
|
0.023x |
|
Petronas Gas Bhd
KLSE:6033
|
0.044x |
|
KT Corporation
NYSE:KT
|
0.066x |
|
SG Micro Corp
SHE:300661
|
0.029x |
|
Bharti Hexacom Ltd
NSE:BHARTIHEXA
|
0.173x |
|
Manhattan Associates Inc
NASDAQ:MANH
|
0.410x |
|
Alstom S.A.
PA:ALO
|
-0.053x |
Annual Cash Flow Conversion Efficiency for Halozyme Therapeutics Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Halozyme Therapeutics Inc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see Halozyme Therapeutics Inc (HALO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $363.82 Million | $479.06 Million | 1.317x | -71.60% |
| 2023-12-31 | $83.81 Million | $388.57 Million | 4.636x | +227.87% |
| 2022-12-31 | $169.80 Million | $240.11 Million | 1.414x | -6.99% |
| 2021-12-31 | $196.95 Million | $299.44 Million | 1.520x | +314.12% |
| 2020-12-31 | $151.05 Million | $55.45 Million | 0.367x | +139.44% |
| 2019-12-31 | $91.77 Million | $-85.42 Million | -0.931x | -368.05% |
| 2018-12-31 | $248.89 Million | $-49.50 Million | -0.199x | -130.91% |
| 2017-12-31 | $208.37 Million | $134.05 Million | 0.643x | -58.52% |
| 2016-12-31 | $-32.48 Million | $-50.38 Million | 1.551x | +279.86% |
| 2015-12-31 | $43.00 Million | $-37.08 Million | -0.862x | +24.95% |
| 2014-12-31 | $41.35 Million | $-47.52 Million | -1.149x | -146.56% |
| 2013-12-31 | $-19.99 Million | $-49.34 Million | 2.468x | +287.44% |
| 2012-12-31 | $48.85 Million | $-64.33 Million | -1.317x | +58.22% |
| 2011-12-31 | $10.90 Million | $-34.35 Million | -3.151x | -41.31% |
| 2010-12-31 | $20.35 Million | $-45.39 Million | -2.230x | +61.65% |
| 2009-12-31 | $6.90 Million | $-40.15 Million | -5.816x | -152.86% |
| 2008-12-31 | $15.38 Million | $-35.37 Million | -2.300x | -89880.87% |
| 2007-12-31 | $57.77 Million | $-147.66K | -0.003x | -100.83% |
| 2006-12-31 | $23.08 Million | $7.08 Million | 0.307x | +142.97% |
| 2005-12-31 | $18.21 Million | $-13.00 Million | -0.714x | -37.11% |
| 2004-12-31 | $14.82 Million | $-7.72 Million | -0.521x | +89.46% |
| 2003-12-31 | $10.06K | $-49.73K | -4.942x | -669.13% |
| 2002-12-31 | $86.81K | $-55.78K | -0.642x | +57.31% |
| 2001-12-31 | $22.84K | $-34.37K | -1.505x | -- |
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more